Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review

References

• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur Heart J. 2018;39(3):213–260. doi:10.1093/eurheartj/ehx419
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. doi:10.1093/eurheartj/ehy394
   PubMed Web of Science ®Google Scholar
• Byrne RA, Xavier Rossello JJC, Barbato E, et al. Roberto E, ESC Scientific Document Group, 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC), Eur Heart J. 2023; ehad191. doi: 10.1093/eurheartj/ehad191
   Google Scholar
• Piccolo R, Oliva A, Avvedimento M, et al. Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. EuroIntervention. 2021;17(7):550–560.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017;38(11):804–810. doi:10.1093/EURHEARTJ/EHW525
   PubMed Web of Science ®Google Scholar
• Capodanno D, Bhatt DL, Gibson CM, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2021;19(2):117–132. doi:10.1038/s41569-021-00598-1
   PubMed Web of Science ®Google Scholar
• Cao D, Chandiramani R, Chiarito M, Claessen BE, Mehran R. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J. 2021;42(4):339–351. doi:10.1093/eurheartj/ehaa824
   PubMed Web of Science ®Google Scholar
• Giustino G, Chieffo A, Palmerini T, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68(17):1851–1864. doi:10.1016/J.JACC.2016.07.760
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Giustino G, et al. Coronary Thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from Paris. J Am Coll Cardiol. 2016;67(19):2224–2234. doi:10.1016/J.JACC.2016.02.064
   PubMed Web of Science ®Google Scholar
• Raposeiras-Roubín S, Faxén J, Íñiguez-romo A, et al. Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: the BleeMACS score. Int J Cardiol. 2018;254:10–15. doi:10.1016/J.IJCARD.2017.10.103
   PubMed Web of Science ®Google Scholar
• De Groot NL, Hagenaars MP, Smeets HM, Steyerberg EW, Siersema PD, Van Oijen MGH. Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts. J Gastroenterol. 2014;49(2):245–253. doi:10.1007/S00535-013-0817-Y
   PubMed Web of Science ®Google Scholar
• Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315(16):1735–1749. doi:10.1001/JAMA.2016.3775
   PubMed Web of Science ®Google Scholar
• Ducrocq G, Wallace JS, Baron G, et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J. 2010;31(10):1257–1265. doi:10.1093/EURHEARTJ/EHQ021
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–1034. doi:10.1016/S0140-6736(17)30397-5
   PubMed Web of Science ®Google Scholar
• Brener SJ, Kirtane AJ, Rinaldi MJ, et al. Prediction of ischemic and bleeding events using the dual antiplatelet therapy score in an unrestricted percutaneous coronary intervention population: analysis from the ADAPT-DES registry. Circ Cardiovasc Interv. 2018;11(10). doi:10.1161/CIRCINTERVENTIONS.118.006853
   Web of Science ®Google Scholar
• Harada Y, Michel J, Lohaus R, et al. Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. Thromb Haemost. 2017;117(10):1989–1999. doi:10.1160/TH17-02-0101
   PubMed Web of Science ®Google Scholar
• Ueda P, Jernberg T, James S, et al. External validation of the DAPT score in a nationwide population. J Am Coll Cardiol. 2018;72(10):1069–1078. doi:10.1016/J.JACC.2018.06.023
   PubMed Web of Science ®Google Scholar
• Witberg G, Zusman O, Yahav D, Perl L, Vaknin-Assa H, Kornowski R. Meta-analysis of studies examining the external validity of the dual antiplatelet therapy score. Eur Heart J Cardiovasc Pharmacother. 2020;6(5):285–291. doi:10.1093/EHJCVP/PVZ075
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J. 2019;40(31):2632–2653. doi:10.1093/eurheartj/ehz372
   PubMed Web of Science ®Google Scholar
• Chiarito M, Luceri L, Oliva A, Stefanini G, Condorelli G. Artificial intelligence and cardiovascular risk prediction: all that glitters is not gold. Eur Cardiol Rev. 2022. doi:10.15420/ECR.2022.11
   PubMed Web of Science ®Google Scholar
• Krittanawong C, Zhang HJ, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. J Am Coll Cardiol. 2017;69(21):2657–2664. doi:10.1016/J.JACC.2017.03.571
   PubMed Web of Science ®Google Scholar
• D’Ascenzo F, De Filippo O, Gallone G, et al. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet. 2021;397(10270):199–207. doi:10.1016/S0140-6736(20)32519-8
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584–2591. doi:10.1016/J.JACC.2006.10.026
   PubMed Web of Science ®Google Scholar
• Serruys PW, Daemen J. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115(11):1455. doi:10.1161/CIRCULATIONAHA.106.666800
   PubMed Web of Science ®Google Scholar
• Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019;393(10190):2503–2510.
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. Engl J Med. 2014;371(23):2155–2166. doi:10.1056/NEJMoa1409312
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015–2026. doi:10.1161/CIRCULATIONAHA.111.071589
   PubMed Web of Science ®Google Scholar
• Collet JP, Silvain J, Barthélémy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (Arctic-Interruption): a randomised trial. Lancet. 2014;384(9954):1577–1585. doi:10.1016/S0140-6736(14)60612-7
   PubMed Web of Science ®Google Scholar
• Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129(3):304–312. doi:10.1161/CIRCULATIONAHA.113.003303
   PubMed Web of Science ®Google Scholar
• Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016;37(4):365–374. doi:10.1093/eurheartj/ehv481
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. Engl J Med. 2015;372(19):1791–1800. doi:10.1056/NEJMoa1500857
   PubMed Web of Science ®Google Scholar
• Gilard M, Barragan P, Noryani AAL, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65(8):777–786. doi:10.1016/j.jacc.2014.11.008
   PubMed Web of Science ®Google Scholar
• Nakamura M, Iijima R, Ako J, et al. Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation. JACC Cardiovasc Interv. 2017;10(12):1189–1198. doi:10.1016/j.jcin.2017.04.019
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309–1320. doi:10.1056/NEJMOA1908077
   PubMed Web of Science ®Google Scholar
• Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385(9985):2371–2382. doi:10.1016/S0140-6736(15)60263-X
   PubMed Web of Science ®Google Scholar
• Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125(3):505–513. doi:10.1161/CIRCULATIONAHA.111.059022
   PubMed Web of Science ®Google Scholar
• Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal Safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340–1348. doi:10.1016/j.jacc.2012.06.043
   PubMed Web of Science ®Google Scholar
• Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310(23):2510–2522. doi:10.1001/jama.2013.282183
   PubMed Web of Science ®Google Scholar
• Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64(20):2086–2097. doi:10.1016/j.jacc.2014.09.008
   PubMed Web of Science ®Google Scholar
• Schulz-Schüpke S, Byrne RA, ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36(20):1252–1263. doi:10.1093/eurheartj/ehu523
   PubMed Web of Science ®Google Scholar
• Han Y, Xu B, Xu K, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv. 2016;9(2). doi:10.1161/CIRCINTERVENTIONS.115.003145
   PubMed Web of Science ®Google Scholar
• Hong SJ, Shin DH, Kim JS, et al. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv. 2016;9(14):1438–1446. doi:10.1016/j.jcin.2016.04.036
   PubMed Web of Science ®Google Scholar
• Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391(10127):1274–1284. doi:10.1016/S0140-6736(18)30493-8
   PubMed Web of Science ®Google Scholar
• Kedhi E, Fabris E, Van Der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018;363. doi:10.1136/BMJ.K3793
   PubMedGoogle Scholar
• Lee BK, Kim JS, Lee OH, et al. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C randomised clinical trial and OCT substudy. EuroIntervention. 2020;13(16):1923–1930.
   Web of Science ®Google Scholar
• de Luca G, Damen SA, Camaro C, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention. 2019;15(11):E990–E998. doi:10.4244/EIJ-D-19-00539
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–2427. doi:10.1001/jama.2019.8145
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. Engl J Med. 2015;373(21):2038–2047. doi:10.1056/NEJMOA1503943/SUPPL_FILE/NEJMOA1503943_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. Engl J Med. 2020;382(13):1208–1218. doi:10.1056/NEJMOA1910021/SUPPL_FILE/NEJMOA1910021_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391(10115):41–50. doi:10.1016/S0140-6736(17)32713-7
   PubMed Web of Science ®Google Scholar
• Mehran R, Cao D, Angiolillo DJ, et al. 3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation. JACC Cardiovasc Interv. 2021;14(17):1870–1883. doi:10.1016/j.jcin.2021.07.016
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. Engl J Med. 2021;385(18):1643–1655. doi:10.1056/NEJMOA2108749/SUPPL_FILE/NEJMOA2108749_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Costa F, Montalto C, Branca M, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. Eur Heart J. 2022. doi:10.1093/EURHEARTJ/EHAC706
   Google Scholar
• Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–949. doi:10.1016/S0140-6736(18)31858-0
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. Engl J Med. 2019;381(21):2032–2042. doi:10.1056/NEJMOA1908419/SUPPL_FILE/NEJMOA1908419_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee YJ, Kim BK, et al. Ticagrelor monotherapy versus ticagrelor with aspirin in acute coronary syndrome patients with a high risk of ischemic events. Circ Cardiovasc Interv. 2021;14:e010812.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022;7(4):407–417. doi:10.1001/JAMACARDIO.2021.5244
   PubMed Web of Science ®Google Scholar
• Choi KH, Park YH, Song B, et al. Long-term effects of P2Y12 inhibitor monotherapy after percutaneous coronary intervention: 3-year follow-up of the SMART-CHOICE randomized clinical trial. JAMA Cardiol. 2022;7(11):1100–1108. doi:10.1001/JAMACARDIO.2022.3203
   PubMed Web of Science ®Google Scholar
• Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428–2437. doi:10.1001/JAMA.2019.8146
   PubMed Web of Science ®Google Scholar
• Obayashi Y, Watanabe H, Morimoto T, et al. Clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 total cohort. Circ Cardiovasc Interv. 2022;15(8):E012004. doi:10.1161/CIRCINTERVENTIONS.122.012004
   PubMed Web of Science ®Google Scholar
• Armstrong PCJ, Leadbeater PD, Chan MV, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011;9(3):552–561. doi:10.1111/J.1538-7836.2010.04160.X
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Baber U, Mehran R. Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Cardiovasc Res. 2020;116(7):E70–E72. doi:10.1093/CVR/CVAA120
   PubMed Web of Science ®Google Scholar
• Escaned J, Cao D, Baber U, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021;42(45):4624–4634. doi:10.1093/EURHEARTJ/EHAB702
   PubMed Web of Science ®Google Scholar
• Dangas G, Baber U, Sharma S, et al. Ticagrelor with or without aspirin after complex PCI. J Am Coll Cardiol. 2020;75(19):2414–2424. doi:10.1016/J.JACC.2020.03.011
   PubMed Web of Science ®Google Scholar
• Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407–2416. doi:10.1001/jama.2020.7580
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021;373:n1332. doi:10.1136/bmj.n1332
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Mehran R, Franzone A, et al. Ticagrelor monotherapy versus dual-antiplatelet therapy after PCI: an individual patient-level meta-analysis. JACC Cardiovasc Interv. 2021;14(4):444–456.
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–1830. doi:10.1001/JAMA.2010.1543
   PubMed Web of Science ®Google Scholar
• Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36(27):1762–1771. doi:10.1093/EURHEARTJ/EHV104
   PubMed Web of Science ®Google Scholar
• Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021. doi:10.1016/j.jcin.2021.01.024
   Web of Science ®Google Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(16):1521–1537. doi:10.1016/j.jcin.2019.03.034
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747–1757. doi:10.1016/S0140-6736(17)32155-4
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;1(1):1. doi:10.1056/NEJMoa1907096
   Google Scholar
• Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324(8):761–771. doi:10.1001/jama.2020.12443
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ, Lennon RJ, et al. ABCD-GENE score and clinical outcomes following percutaneous coronary intervention: insights from the TAILOR-PCI trial. J Am Heart Assoc. 2022;11(4):24156. doi:10.1161/JAHA.121.024156
   PubMed Web of Science ®Google Scholar
• Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021;397(10283):1470–1483. doi:10.1016/S0140-6736(21)00533-X
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. doi:10.1136/bmj.324.7329.71
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a Phase 3, placebo-controlled, randomised trial. Lancet. 2019;394(10204):1169–1180. doi:10.1016/S0140-6736(19)31887-2
   PubMed Web of Science ®Google Scholar
• Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395(10235):1487–1495. doi:10.1016/S0140-6736(20)30315-9
   PubMed Web of Science ®Google Scholar
• Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397(10293):2487–2496. doi:10.1016/S0140-6736(21)01063-1
   PubMed Web of Science ®Google Scholar
• Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. 2023;147(2):108–117. doi:10.1161/CIRCULATIONAHA.122.062770
   PubMed Web of Science ®Google Scholar
• Valgimigli M. P2Y12 inhibitor or aspirin monotherapy as secondary prevention in patients with coronary artery disease: an individual participant data meta-analysis of randomised controlled trials. Presented at: ESC 2022; Barcelona, Spain; 2022.
   Google Scholar
• Baber U, Kini AS, Sharma SK. Stenting of complex lesions: an overview. Nat Rev Cardiol. 2010;7(9):485–496. doi:10.1038/NRCARDIO.2010.116
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Shiomi H, Morimoto T, et al. Ischemic and bleeding risk after complex percutaneous coronary intervention in patients with or without high bleeding risk. Catheter Cardiovasc Interv. 2021;97(6):E758–E770. doi:10.1002/CCD.29335
   PubMed Web of Science ®Google Scholar
• Costa F, Van Klaveren D, Feres F, et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019;73(7):741–754.
   PubMed Web of Science ®Google Scholar
• Silvain J, Lattuca B, Beygui F, et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet. 2020;396(10264):1737–1744. doi:10.1016/S0140-6736(20)32236-4
   PubMed Web of Science ®Google Scholar
• Oliva A, Castiello DS, Franzone A, et al. P2Y12 inhibitors monotherapy in patients undergoing complex vs non-complex percutaneous coronary intervention: a meta-analysis of randomized trials. Am Heart J. 2023;255:71–81. doi:10.1016/J.AHJ.2022.10.006
   PubMed Web of Science ®Google Scholar
• Nicolas J, Dangas G, Chiarito M, et al. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022. doi:10.1093/EHJCVP/PVAC071
   Web of Science ®Google Scholar
• Gragnano F, Mehran R, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol. 2023;81(6):537–552. doi:10.1016/J.JACC.2022.11.041
   PubMed Web of Science ®Google Scholar
• Capodanno D, Milluzzo RP, Angiolillo DJ. Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. Ther Adv Cardiovasc Dis. 2019;13. doi:10.1177/1753944719893274/ASSET/IMAGES/LARGE/10.1177_1753944719893274-FIG2.JPEG
   Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14). doi:10.1056/NEJMOA1300815
   Web of Science ®Google Scholar
• Stone GW, Généreux P, Harrington RA, et al. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION Phoenix trial. Eur Heart J. 2018;39(46):4112–4121. doi:10.1093/EURHEARTJ/EHY562
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas A, et al. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2019;139(14):1661–1670. doi:10.1161/CIRCULATIONAHA.118.038317
   PubMed Web of Science ®Google Scholar
• Sumaya W, Parker WAE, Fretwell R, et al. Pharmacodynamic effects of a 6-hour regimen of enoxaparin in patients undergoing primary percutaneous coronary intervention (PENNY PCI study). Thromb Haemost. 2018;118(7). doi:10.1055/s-0038-1657768
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265–274. doi:10.1001/JAMA.2011.2002
   PubMed Web of Science ®Google Scholar
• Cao D, Chandiramani R, Capodanno D, et al. Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. Nat Rev Cardiol. 2021;18(1):37–57. doi:10.1038/S41569-020-0410-Z
   PubMed Web of Science ®Google Scholar
• Rossini R, Tarantini G, Musumeci G, et al. A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery: surgery after stenting 2. JACC Cardiovasc Interv. 2018;11(5):417–434. doi:10.1016/J.JCIN.2017.10.051
   PubMed Web of Science ®Google Scholar
• Parker WAE, Storey RF. Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist. Expert Opin Emerg Drugs. 2020;25(1):1–6. doi:10.1080/14728214.2020.1729121
   PubMed Web of Science ®Google Scholar
• Sinnaeve P, Fahrni G, Schelfaut D, et al. Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction. J Am Coll Cardiol. 2020;75(20):2588–2597. doi:10.1016/J.JACC.2020.03.059
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. Engl J Med. 2016;375(25):2423–2434. doi:10.1056/NEJMOA1611594/SUPPL_FILE/NEJMOA1611594_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. Engl J Med. 2017;377(16):1513–1524. doi:10.1056/NEJMOA1708454/SUPPL_FILE/NEJMOA1708454_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. Engl J Med. 2019;380(16):1509–1524. doi:10.1056/NEJMOA1817083/SUPPL_FILE/NEJMOA1817083_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–1343. doi:10.1016/S0140-6736(19)31872-0
   PubMed Web of Science ®Google Scholar
• Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. Engl J Med. 2019;381(12):1103–1113. doi:10.1056/NEJMOA1904143/SUPPL_FILE/NEJMOA1904143_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2021;143(6):583–596. doi:10.1161/CIRCULATIONAHA.120.050438
   PubMed Web of Science ®Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):E344–E418. doi:10.1161/STR.0000000000000211
   PubMed Web of Science ®Google Scholar
• Chen ZM. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349(9066):1641–1649. doi:10.1016/S0140-6736(97)04010-5
   PubMed Web of Science ®Google Scholar
• Sandercock PAG. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet. 1997;349(9065):1569–1581. doi:10.1016/S0140-6736(97)04011-7
   PubMed Web of Science ®Google Scholar
• Gent M. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339. doi:10.1016/S0140-6736(96)09457-3
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Ince B, Hu B, et al. Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis. Cardiovasc Ther. 2019;2019. doi:10.1155/2019/1607181
   PubMed Web of Science ®Google Scholar
• Diener PHC, Bogousslavsky PJ, Brass PLM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–337. doi:10.1016/S0140-6736(04)16721-4
   PubMed Web of Science ®Google Scholar
• Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. Engl J Med. 2008;359(12):1238–1251. doi:10.1056/NEJMOA0805002
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. Engl J Med. 2016;375(1):35–43. doi:10.1056/NEJMOA1603060
   PubMed Web of Science ®Google Scholar
• Fergus IV. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. Cardiol Rev. 2012;28(6). doi:10.1056/NEJMOA1204133
   Google Scholar
• Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Engl J Med. 2006;354(16):1706–1717. doi:10.1056/NEJMOA060989
   PubMed Web of Science ®Google Scholar
• Johnston SC, Amarenco P, Denison H, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. Engl J Med. 2020;383(3):207–217. doi:10.1056/NEJMOA1916870/SUPPL_FILE/NEJMOA1916870_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharma. Eur Heart J. 2021. doi:10.1093/eurheartj/ehab390
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982–1988. doi:10.1016/j.jacc.2007.03.025
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Fowkes FGR, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. Engl J Med. 2017;376(1):32–40. doi:10.1056/NEJMOA1611688
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. Engl J Med. 2017;377(14):1319–1330. doi:10.1056/NEJMoa1709118
   PubMed Web of Science ®Google Scholar
• Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. doi:10.1016/S0140-6736(17)32409-1
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. Engl J Med. 2020;382(21):1994–2004. doi:10.1056/NEJMOA2000052
   PubMed Web of Science ®Google Scholar